Novartis said it plans to invest $23 billion in the construction and expansion of U.S. facilities. The move comes after President Trump earlier this week threatened "major" tariffs on pharmaceuticals.

The Novartis Gene Therapies manufacturing facility on Tricenter Blvd. in Durham, N.C., just outside Research Triangle Park. Brian Gordon Swiss pharmaceutical giant Novartis has exited one of its ...

Novartis broke through in May 2019 with the FDA approval of Zolgensma, the first gene therapy for SMA. “When it comes to the mostly newborn, the young kids, we have seen transformative results there,” ...

In 2022, Novartis said it would cut 8,000 jobs globally, Reuters reported, a move that would save the company $1 billion over the next two years. Additionally, the company spun off its generics ...

Novartis has also been examining Lutathera for other indications. In September, it released Phase 2 data on Lutathera improving progression-free survival in patients with meningioma brain tumors. The ...

Novartis is paying Generate:Biomedicines $65 million up front in an AI drug development deal, and milestone payments could exceed $1 billion.

Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court ...

Novartis American depositary receipts (ADRs) slipped Thursday even though the pharmaceutical giant beat second-quarter earnings expectations and raised its full-year core operating income guidance.

A Novartis executive said “it’s too early to say” whether the company would submit an experimental myelofibrosis drug for approval this year, amid questions about the medicine’s data profile.

Pharmaceutical giant Novartis is shutting down a San Diego facility as part of a broader restructuring of the company’s drug development segment. In the first phase of layoffs, the Basel ...

Novartis is committing $100 million to Voyager Therapeutics to see if the biotech’s technology can lead to new gene therapies for Huntington’s disease and spinal muscular atrophy.. According ...

Deal Overview On July 18, 2023, Novartis AG (NYSE: NVS, $105.01, Market Capitalization $239.2 billion), a leading global medicine company, announced that its Board of ...